TABLE 1.
Demographic, clinical and procedural characteristics of the subjects
| Factor | (n=20) |
|---|---|
| Age, years, mean ± SD | 62.5±11.3 |
| Male sex | 12 (60.0) |
| Body mass index, kg/m2, mean ± SD | 21.9±3.5 |
| Smoking (current and ex) | 8 (40.0) |
| Alcohol abuse (current and ex) | 4 (20.0) |
| Regular narcotic/sedative use | 1 (5.0) |
| Sleep apnea | 0 (0) |
| Mallampati score | |
| 1 | 4 (20.0) |
| 2 | 9 (45.0) |
| 3 | 1 (5.0) |
| 4 | 6 (30) |
| ASA class | |
| 1 | 0 (0) |
| 2 | 7 (35.0) |
| 3 | 12 (60.0) |
| 4 | 1 (5.0) |
| Sedation problems during previous endoscopies | 0 (0) |
| Inpatients | 19 (95.0) |
| Outpatients | 1 (5.0) |
| Indications | |
| Benign biliary stenosis | 6 (30.0) |
| Biliodigestive anastomosis | 4 (20.0) |
| Chronic pancreatitis | 2 (10.0) |
| Malignant biliary stenosis | 14 (70.0) |
| Cholangiocellular carcinoma | 5 (25.0) |
| Pancreatic cancer | 5 (25.0) |
| Gastric cancer | 3 (15.0) |
| Hepatocellular carcinoma | 1 (5.0) |
| New PTCD | 8 (40.0) |
| PTCD exchange | 6 (30.0) |
| PTCD dilation | 6 (30.0) |
| Baseline oxygen saturation, %, mean ± SD | 99.4±0.8 |
| Baseline heart rate, beats/min, mean ± SD | 82.6±15.6 |
| Baseline systolic blood pressure, mmHg, mean ± SD | 141.4±23.9 |
| Procedural time, min, mean ± SD | 32.9±21.2 |
| Total midazolam dose, mg, mean ± SD | 2.5±0 |
| Total propofol dose, mg, mean ± SD | 274.3±222.8 |
Data presented as n (%) unless otherwise indicated. ASA American Association of Anesthesiologists; PTCD Percutaneous transhepatic cholangiodrainage